Form 4: 4D Molecular Therapeutics Officer Uneek Mehra Reports Stock Option Grant
SEC Filing
Uneek Mehra, Chief Financial & Business Officer of 4D Molecular Therapeutics, reports the acquisition of stock options.
Summary
- Uneek Mehra, Chief Financial & Business Officer of 4D Molecular Therapeutics, filed a Form 4 on March 10, 2025.
- The report details the acquisition of stock options to purchase 130,000 shares of common stock at an exercise price of $4.14 on March 6, 2025.
- The options vest monthly, starting March 6, 2025, over four years, becoming fully vested on the fourth anniversary, provided Mehra remains a service provider to the company.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants.
Positives
- The vesting schedule incentivizes continued service to the company.
Industry Context
This filing is a routine disclosure of insider transactions, common in publicly traded companies to ensure transparency and compliance with securities regulations.
Stakeholder Impact
- The stock option grant aligns the officer's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of earliest transaction (stock option grant) |
| 03/06/2025 | Vesting Commencement Date |
| 03/10/2025 | Date of Form 4 filing |
| 03/05/2035 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.